WO1996040139A1 - Novel formulations for transdermal delivery of pergolide - Google Patents
Novel formulations for transdermal delivery of pergolide Download PDFInfo
- Publication number
- WO1996040139A1 WO1996040139A1 PCT/US1996/009692 US9609692W WO9640139A1 WO 1996040139 A1 WO1996040139 A1 WO 1996040139A1 US 9609692 W US9609692 W US 9609692W WO 9640139 A1 WO9640139 A1 WO 9640139A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pergolide
- reservoir
- permeation enhancer
- membrane
- permeation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9501953A JPH11507361A (en) | 1995-06-07 | 1996-06-07 | A new formulation for percutaneous release of pergolide |
AU64764/96A AU6476496A (en) | 1995-06-07 | 1996-06-07 | Novel formulations for transdermal delivery of pergolide |
DE69637061T DE69637061T2 (en) | 1995-06-07 | 1996-06-07 | A composition and device for administering pergolide at a therapeutically effective rate |
EP95929346A EP0831827B1 (en) | 1995-06-07 | 1996-06-07 | Novel formulations for transdermal delivery of pergolide |
DE19681435T DE19681435T1 (en) | 1995-06-07 | 1996-06-07 | New formulations for the transdermal delivery of pergolide |
GB9724267A GB2316004B (en) | 1995-06-07 | 1996-06-07 | Novel formulations for transdermal delivery of pergolide |
DK95929346T DK0831827T3 (en) | 1995-06-07 | 1996-06-07 | New formulations for transdermal delivery of pergolide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/473,631 US6572879B1 (en) | 1995-06-07 | 1995-06-07 | Formulations for transdermal delivery of pergolide |
US08/473,631 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996040139A1 true WO1996040139A1 (en) | 1996-12-19 |
Family
ID=23880356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/009692 WO1996040139A1 (en) | 1995-06-07 | 1996-06-07 | Novel formulations for transdermal delivery of pergolide |
Country Status (12)
Country | Link |
---|---|
US (3) | US6572879B1 (en) |
EP (2) | EP0831827B1 (en) |
JP (2) | JPH11507361A (en) |
AT (1) | ATE361073T1 (en) |
AU (1) | AU6476496A (en) |
CA (1) | CA2221263A1 (en) |
DE (2) | DE69637061T2 (en) |
DK (1) | DK0831827T3 (en) |
ES (1) | ES2285704T3 (en) |
GB (1) | GB2316004B (en) |
PT (1) | PT831827E (en) |
WO (1) | WO1996040139A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000142A1 (en) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Plaster for the transdermal application of pergolide |
WO1998017315A2 (en) * | 1996-10-24 | 1998-04-30 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
WO1999059558A1 (en) * | 1998-05-15 | 1999-11-25 | Schwarz Pharma Ag | Transdermal therapeutic system containing pergolide |
DE10110953A1 (en) * | 2001-03-07 | 2002-09-19 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for the administration of partial dopamine D2 agonists |
WO2002078602A2 (en) * | 2001-03-30 | 2002-10-10 | Elan Pharmaceuticals, Inc. | Transdermal delivery of pergolide |
US6623752B1 (en) | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
WO2004019987A1 (en) * | 2002-08-28 | 2004-03-11 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
WO2004019988A1 (en) * | 2002-08-28 | 2004-03-11 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
EP1679075A1 (en) * | 2003-10-31 | 2006-07-12 | Hisamitsu Pharmaceutical Co. Inc. | Transdermal preparations and method for relieving side effects in pergolide therapy |
GB2450533A (en) * | 2007-06-29 | 2008-12-31 | Ferring Int Ct Sa | Treatment and prevention of endometriosis using dopamine agonists. |
US8927568B2 (en) | 2007-02-01 | 2015-01-06 | Ferring International Center S.A. | Medicament for the treatment of endometriosis |
EP1666026B2 (en) † | 1999-02-08 | 2015-02-25 | Intarcia Therapeutics, Inc | Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same |
US8992961B2 (en) | 1999-02-08 | 2015-03-31 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
WO2019234069A1 (en) | 2018-06-08 | 2019-12-12 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising pergolide |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572879B1 (en) * | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
DE10043321B4 (en) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition |
DE10053397A1 (en) * | 2000-10-20 | 2002-05-02 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
DE10341317B4 (en) * | 2003-09-03 | 2008-10-23 | Axxonis Pharma Ag | Transdermal therapeutic system (TTS) for administration of ergoline compounds except pergolide |
GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
DE10064453A1 (en) * | 2000-12-16 | 2002-07-04 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
FR2823999B1 (en) * | 2001-04-27 | 2003-06-27 | Commissariat Energie Atomique | MINIATURE DEVICE FOR SEPARATING AND ISOLATING BIOLOGICAL OBJECTS AND USES |
EP1392272B1 (en) * | 2001-05-11 | 2014-08-06 | Merrion Research III Limited | Permeation enhancers |
US20040120995A1 (en) * | 2002-04-01 | 2004-06-24 | Martin Debra A | Transdermal delivery of pergolide |
EA200401565A1 (en) * | 2002-05-24 | 2005-04-28 | Неофарм, Инк. | METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS) |
JP2006518701A (en) * | 2002-05-24 | 2006-08-17 | ネオファーム、インコーポレイティッド | Cardiolipin composition, process for its production and use |
US20050277611A1 (en) * | 2002-10-16 | 2005-12-15 | Neopharm, Inc. | Cationic cardiolipin analoges and its use thereof |
AU2004233997C1 (en) | 2003-04-29 | 2014-01-30 | Massachusetts Institiute Of Technology | Methods and devices for the sustained release of multiple drugs |
US20050191338A1 (en) * | 2004-01-30 | 2005-09-01 | Lifeng Kang | Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof |
DE102005050431A1 (en) * | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the administration of lipophilic and / or less skin-permeable active ingredients |
CA2648594C (en) | 2006-04-07 | 2012-10-16 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US20070292512A1 (en) * | 2006-06-09 | 2007-12-20 | Merrion Research Ii Limited | Solid Oral Dosage Form Containing an Enhancer |
US20090280169A1 (en) | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
US20130274352A1 (en) * | 2009-04-14 | 2013-10-17 | The Regents Of The University Of California | Oral Drug Devices and Drug Formulations |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
US9072682B2 (en) | 2012-12-31 | 2015-07-07 | Mylan Inc. | Transdermal dosage form for low-melting point active agent |
JP7211704B2 (en) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | A tablet containing a GLP-1 agonist and an enteric coating |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000746A1 (en) * | 1989-07-12 | 1991-01-24 | Cygnus Research Corporation | Transdermal administration of lisuride |
EP0458640A2 (en) * | 1990-05-25 | 1991-11-27 | Eli Lilly And Company | Use of ergoline derivatives for the treatment of diseases associated with bone demineralization |
DE4240798A1 (en) * | 1991-12-03 | 1993-06-09 | Poli Industria Chimica S.P.A., Mailand/Milano, It | Neuro-protective agents preventing nerve damage - contain ergot derivs. e.g. clavine lysergic acid amide or 8-alpha-amino:ergoline derivs. |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
JPH0240647B2 (en) * | 1978-02-08 | 1990-09-12 | Lilly Co Eli | PURORAKUCHIN BUNPYOKUSEIZAI |
JPH0240044B2 (en) * | 1978-02-08 | 1990-09-10 | Lilly Co Eli | PAAKINSONSHOKOGUNCHIRYOZAI |
US4166182A (en) | 1978-02-08 | 1979-08-28 | Eli Lilly And Company | 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4849226A (en) | 1981-06-29 | 1989-07-18 | Alza Corporation | Method for increasing oxygen supply by administering vasodilator |
US4435180A (en) | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
US4559222A (en) | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
US4704282A (en) | 1984-06-29 | 1987-11-03 | Alza Corporation | Transdermal therapeutic system having improved delivery characteristics |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4675322A (en) * | 1984-12-10 | 1987-06-23 | Eli Lilly And Company | 1-Substituted-6-n-propyl-8β-methylthio-methylergolines |
US4645502A (en) | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
US4782152A (en) * | 1985-08-16 | 1988-11-01 | Eli Lilly And Company | Decyanation of pergolide intermediate |
US4935429A (en) | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
US4908027A (en) | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
US4800204A (en) | 1987-05-07 | 1989-01-24 | Mueller Peter S | Method of controlling tobacco use |
US4764379A (en) | 1987-08-24 | 1988-08-16 | Alza Corporation | Transdermal drug delivery device with dual permeation enhancers |
US4943435A (en) | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
US4797405A (en) | 1987-10-26 | 1989-01-10 | Eli Lilly And Company | Stabilized pergolide compositions |
US4814168A (en) * | 1988-03-04 | 1989-03-21 | Noven Pharmaceuticals, Inc. | Transdermal multipolymer drug delivery system |
US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5378730A (en) * | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
US4973468A (en) * | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
US5229129A (en) | 1989-07-12 | 1993-07-20 | Cygnus Therapeutic Systems | Transdermal administration of lisuride |
US5114948A (en) * | 1989-10-19 | 1992-05-19 | Eli Lilly And Company | Stabilized pergolide compositions |
US5314694A (en) | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
JP3255717B2 (en) * | 1991-08-08 | 2002-02-12 | 積水化学工業株式会社 | Transdermal formulation |
CA2090598A1 (en) | 1992-03-04 | 1993-09-05 | Kirti Himatlal Valia | Titratable transdermal patch system and method for administration of therapeutic substances |
JPH05271658A (en) * | 1992-03-27 | 1993-10-19 | Chisso Corp | Antiferroelectric liquid crystal composition |
JPH08501529A (en) * | 1992-06-11 | 1996-02-20 | セラテック・インコーポレイテッド | Use of glycerin to alleviate skin-penetrating drug administration |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
ATE149349T1 (en) * | 1993-06-25 | 1997-03-15 | Alza Corp | INCORPORATING A POLY-N-VINYLAMIDE INTO A TRANSDERMAL SYSTEM |
AU676430B2 (en) * | 1994-03-07 | 1997-03-06 | Theratech, Inc. | Drug-containing adhesive composite transdermal delivery device |
US6572879B1 (en) * | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
-
1995
- 1995-06-07 US US08/473,631 patent/US6572879B1/en not_active Expired - Lifetime
-
1996
- 1996-06-07 CA CA002221263A patent/CA2221263A1/en not_active Abandoned
- 1996-06-07 DE DE69637061T patent/DE69637061T2/en not_active Expired - Lifetime
- 1996-06-07 EP EP95929346A patent/EP0831827B1/en not_active Expired - Lifetime
- 1996-06-07 JP JP9501953A patent/JPH11507361A/en active Pending
- 1996-06-07 WO PCT/US1996/009692 patent/WO1996040139A1/en active IP Right Grant
- 1996-06-07 AU AU64764/96A patent/AU6476496A/en not_active Abandoned
- 1996-06-07 AT AT95929346T patent/ATE361073T1/en active
- 1996-06-07 DE DE19681435T patent/DE19681435T1/en not_active Withdrawn
- 1996-06-07 DK DK95929346T patent/DK0831827T3/en active
- 1996-06-07 PT PT95929346T patent/PT831827E/en unknown
- 1996-06-07 GB GB9724267A patent/GB2316004B/en not_active Expired - Lifetime
- 1996-06-07 EP EP04075596A patent/EP1428527A1/en not_active Withdrawn
- 1996-06-07 ES ES95929346T patent/ES2285704T3/en not_active Expired - Lifetime
- 1996-12-18 US US08/768,600 patent/US6001390A/en not_active Expired - Lifetime
-
2002
- 2002-04-09 US US10/121,478 patent/US20040209909A1/en not_active Abandoned
-
2007
- 2007-06-27 JP JP2007168802A patent/JP2007238636A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000746A1 (en) * | 1989-07-12 | 1991-01-24 | Cygnus Research Corporation | Transdermal administration of lisuride |
EP0458640A2 (en) * | 1990-05-25 | 1991-11-27 | Eli Lilly And Company | Use of ergoline derivatives for the treatment of diseases associated with bone demineralization |
DE4240798A1 (en) * | 1991-12-03 | 1993-06-09 | Poli Industria Chimica S.P.A., Mailand/Milano, It | Neuro-protective agents preventing nerve damage - contain ergot derivs. e.g. clavine lysergic acid amide or 8-alpha-amino:ergoline derivs. |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000142A1 (en) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Plaster for the transdermal application of pergolide |
US6623752B1 (en) | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
WO1998017315A2 (en) * | 1996-10-24 | 1998-04-30 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
WO1998017315A3 (en) * | 1996-10-24 | 1998-07-02 | Alza Corp | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
US6004578A (en) * | 1996-10-24 | 1999-12-21 | Alza Corporation | Permeation enhances for transdermal drug delivery compositions, devices and methods |
WO1999059558A1 (en) * | 1998-05-15 | 1999-11-25 | Schwarz Pharma Ag | Transdermal therapeutic system containing pergolide |
DE19821788C1 (en) * | 1998-05-15 | 1999-12-02 | Sanol Arznei Schwarz Gmbh | Transdermal therapeutic system (TTS) containing pergolide |
JP2002515424A (en) * | 1998-05-15 | 2002-05-28 | シュバルツ ファルマ アクチェンゲゼルシャフト | Pergolide-containing transdermal therapeutic system (TTS) |
US6461636B1 (en) * | 1998-05-15 | 2002-10-08 | Schwarz Pharma Ag | Transdermal therapeutic system containing pergolide |
EP1666026B2 (en) † | 1999-02-08 | 2015-02-25 | Intarcia Therapeutics, Inc | Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same |
US8992961B2 (en) | 1999-02-08 | 2015-03-31 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
DE10110953A1 (en) * | 2001-03-07 | 2002-09-19 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for the administration of partial dopamine D2 agonists |
WO2002078602A3 (en) * | 2001-03-30 | 2003-02-20 | Elan Transdermal Technologies | Transdermal delivery of pergolide |
WO2002078602A2 (en) * | 2001-03-30 | 2002-10-10 | Elan Pharmaceuticals, Inc. | Transdermal delivery of pergolide |
WO2004019988A1 (en) * | 2002-08-28 | 2004-03-11 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
CN100341576C (en) * | 2002-08-28 | 2007-10-10 | 久光制药株式会社 | Adhesive patch |
US8691267B2 (en) | 2002-08-28 | 2014-04-08 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
WO2004019987A1 (en) * | 2002-08-28 | 2004-03-11 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
EP1679075A1 (en) * | 2003-10-31 | 2006-07-12 | Hisamitsu Pharmaceutical Co. Inc. | Transdermal preparations and method for relieving side effects in pergolide therapy |
EP1679075A4 (en) * | 2003-10-31 | 2010-06-09 | Hisamitsu Pharmaceutical Co | Transdermal preparations and method for relieving side effects in pergolide therapy |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US10363287B2 (en) | 2005-02-03 | 2019-07-30 | Intarcia Therapeutics, Inc. | Method of manufacturing an osmotic delivery device |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US9023862B2 (en) | 2007-02-01 | 2015-05-05 | Ferring International Center S.A. | Medicament for the treatment of endometriosis |
US8927568B2 (en) | 2007-02-01 | 2015-01-06 | Ferring International Center S.A. | Medicament for the treatment of endometriosis |
GB2450533A (en) * | 2007-06-29 | 2008-12-31 | Ferring Int Ct Sa | Treatment and prevention of endometriosis using dopamine agonists. |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10441528B2 (en) | 2008-02-13 | 2019-10-15 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10869830B2 (en) | 2009-09-28 | 2020-12-22 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10583080B2 (en) | 2014-09-30 | 2020-03-10 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11214607B2 (en) | 2016-05-16 | 2022-01-04 | Intarcia Therapeutics Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11840559B2 (en) | 2016-05-16 | 2023-12-12 | I2O Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD912249S1 (en) | 2016-06-02 | 2021-03-02 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD962433S1 (en) | 2016-06-02 | 2022-08-30 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US11654183B2 (en) | 2017-01-03 | 2023-05-23 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of exenatide and co-administration of a drug |
WO2019234069A1 (en) | 2018-06-08 | 2019-12-12 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising pergolide |
Also Published As
Publication number | Publication date |
---|---|
GB9724267D0 (en) | 1998-01-14 |
PT831827E (en) | 2007-07-20 |
GB2316004B (en) | 1999-08-04 |
GB2316004A (en) | 1998-02-18 |
US6001390A (en) | 1999-12-14 |
US20040209909A1 (en) | 2004-10-21 |
DE69637061D1 (en) | 2007-06-14 |
EP0831827B1 (en) | 2007-05-02 |
ES2285704T3 (en) | 2007-11-16 |
DE69637061T2 (en) | 2008-01-10 |
US6572879B1 (en) | 2003-06-03 |
JP2007238636A (en) | 2007-09-20 |
DE19681435T1 (en) | 1998-07-23 |
DK0831827T3 (en) | 2007-09-10 |
EP0831827A1 (en) | 1998-04-01 |
AU6476496A (en) | 1996-12-30 |
MX9709872A (en) | 1998-08-30 |
EP1428527A1 (en) | 2004-06-16 |
CA2221263A1 (en) | 1996-12-19 |
ATE361073T1 (en) | 2007-05-15 |
JPH11507361A (en) | 1999-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6572879B1 (en) | Formulations for transdermal delivery of pergolide | |
US7011844B2 (en) | Formulations for the administration of fluoxetine | |
AU679794B2 (en) | Monoglyceride/lactate ester permeation enhancer for oxybutynin | |
EP0946184B1 (en) | Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate | |
US5198223A (en) | Transdermal formulations, methods and devices | |
US5900250A (en) | Monoglyceride/lactate ester permeation enhancer for oxybutnin | |
NZ240358A (en) | Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer | |
WO1994021262A1 (en) | Device for the transdermal administration of alprazolam | |
US6699497B1 (en) | Formulations for the transdermal administration of fenoldopam | |
US20010051181A1 (en) | Novel formulations for the transdermal administration of asimadoline | |
EP1100476B1 (en) | Formulations for the transdermal administration of fenoldopam | |
EP1393724B1 (en) | Novel formulations for the transdermal administration of fluoxetine | |
EP1216036B1 (en) | Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines | |
WO1999032096A1 (en) | Novel formulations for the transdermal administration of asimadoline | |
MXPA97009872A (en) | Novelty formulations for pergoltranseric supply | |
US20040258742A1 (en) | Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2221263 Country of ref document: CA Ref document number: 2221263 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9724267.1 Country of ref document: GB |
|
ENP | Entry into the national phase |
Ref document number: 1997 501953 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/009872 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995929346 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995929346 Country of ref document: EP |
|
RET | De translation (de og part 6b) |
Ref document number: 19681435 Country of ref document: DE Date of ref document: 19980723 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19681435 Country of ref document: DE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995929346 Country of ref document: EP |